Multifunctional biological composite scaffold for repairing supercritical bone defect and preparation method thereof
Through the multifunctional biocomposite scaffold of PLLA and n-HA composite precipitation and nano-silver and bone flavonoid hydrogel, the problem of repairing supercritical bone defects is solved, the mechanical properties and degradation cycles are matched, the antibacterial, anti-inflammatory and osteogenic induction ability is improved, the risk of cytotoxicity is reduced, and the multi-dimensional repair of complex bone defects is adapted to.
Patent Information
- Application Number
- CN202510500406.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-21
- Publication Date
- 2025-07-18
AI Technical Summary
The prior art is difficult to effectively repair supercritical bone defects, and cannot meet the needs of structural support and mechanical adaptation, biological activity regulation, anti-infection and promotion of regeneration, matching between material degradation rate and new bone regeneration rate, balance between biosafety and multiple biological activities, personalized adaptation and large-scale production.
The medical grade levoligopolylactic acid (PLLA) and nano-hydroxyapatite (n-HA) composite precipitation was used to form a high-strength and tough substrate, combined with nanosilver particles and bone flavonoid-loaded hydrogel, and multifunctional biocomposite scaffolds were prepared through FDM 3D printing technology to achieve the biphasic mechanical properties of bionic bone and dynamic drug sustained release.
The mechanical properties of the stent match the degradation cycle and bone regeneration speed are achieved, which significantly improves the antibacterial, anti-inflammatory and osteogenetic induction capabilities, reduces the risk of cytotoxicity, adapts to the multi-dimensional repair needs of complex bone defects, and simplifies the production process.
Smart Images

Figure CN120324683A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of bone repair materials, and particularly relates to a multifunctional biological composite scaffold for repairing supercritical bone defects and a preparation method thereof. Background Art
[0002] Disclosing the information of this background art section is only intended to enhance the overall understanding of the present invention, and it is not necessarily regarded as an admission or an implication in any form that this information constitutes the prior art already known to those of ordinary skill in the art.
[0003] Supercritical bone defects caused by osteoporosis, tumor resection, accidental trauma, congenital malformations, etc. have always been one of the major challenges in clinical practice. Supercritical bone defects (critical-sized bone defects) refer to the type of bone defects that cannot be healed through the body's own repair mechanism. Currently, traditional bone defect repair materials used clinically face various dilemmas, and their repair needs to meet three core requirements: structural support and mechanical adaptation; biological activity regulation; anti-infection and pro-regeneration synergy. At the same time, three core contradictions need to be solved: the spatio-temporal matching contradiction between the material degradation rate and the new bone regeneration rate; the balance contradiction between biological safety and multiple biological activities; the contradiction between personalized adaptation and large-scale production.
[0004] The existing technical system has the following systematic defects: (1) limitations of autologous / allogeneic transplantation materials; (2) functional defects of single materials; (3) mismatch between the structural and mechanical functions of traditional composite scaffolds and natural bone; (4) imbalance between the degradation rate and the bone regeneration rate; (5) insufficient biological activity of traditional bone repair materials, such as insufficient osteoinductive ability, osteoconductive ability, antibacterial and anti-inflammatory ability, immune rejection and limitations in biocompatibility; (6) technical bottlenecks of existing bioactive drug delivery systems, such as defects in growth factor delivery systems and technical barriers in loading traditional Chinese medicine components; (7) conflict between high-efficiency production and personalized needs; (8) damage to material properties by the sterilization process.
[0005] Patent CN119499449A discloses a modified zinc oxide-based bone implant scaffold material. The scaffold material takes modified zinc oxide as the core and is doped with metals such as silver and molybdenum. It mainly relies on enhancing photocatalytic antibacterial properties (against Gram-positive bacteria) and bone repair ability, but does not mention anti-inflammatory, osteoinductive activity or broad-spectrum antibacterial properties. Although silver metal is doped therein, its function is limited. Its purpose is to enhance the ability of zinc oxide and ignores the biological action ability of other metals. And the modified zinc oxide in this patent can produce cytotoxicity at high concentrations (such as Zn 2+(over-release), and the long-term biocompatibility of the methacrylated hydrogel has not been fully verified. In addition, its antibacterial effect relies on ultrasonic-excited photocatalytic reactions, which may cause oxidative stress damage to surrounding tissues. The degradation of its hydrogel, which uses methacrylated gelatin / chitosan, depends on enzymes secreted by bacteria (such as gelatinase) and lacks active regulation. Moreover, the polyether ether ketone stent or hydroxyapatite stent used for perfusion 3D printing of bone implant scaffolds in this patent has poor toughness and rigidity.
[0006] Patent CN115970054B discloses a 3D printed porous bone scaffold loaded with silicon nitride and its preparation method. The silicon nitride scaffold has certain advantages in osteoinductive activity, but its function is single (only promoting bone regeneration), and the scaffold does not introduce a drug carrier (such as a hydrogel), making it impossible to achieve the controlled release of anti-inflammatory, antibacterial, or pro-angiogenic drugs and difficult to meet the requirements of complex bone microenvironments. The silk fibroin / gelatin system relies on physical cross-linking, and the matching of the degradation rate with the bone regeneration rate has not been clearly verified, which may lead to premature disintegration or residue of the scaffold and insufficient controllability of degradation. Moreover, limited by the low-temperature 3D printing technology, pre-cooling treatment and a low-temperature platform are required, the process is complex and may increase production costs, making it difficult to scale up. In summary, it is difficult to meet the clinical needs of supercritical bone defects (large size, easy to infect, complex morphology).
[0007] Therefore, it is an urgent exploration for those skilled in the art to prepare a multifunctional composite material that simultaneously has excellent mechanical properties, angiogenesis promotion, osteoinduction, antibacterial / anti-inflammatory ability, biological activity, controllable degradation rate, low cytotoxicity, and is personalized to fit the complex morphology of bone defects. Summary of the Invention
[0008] To solve the above problems, the present invention provides a multifunctional biological composite scaffold for repairing supercritical bone defects and its preparation method. The present invention uses medical-grade poly-L-lactic acid (PLLA) as the organic phase and nano-hydroxyapatite (n-HA) as the inorganic phase to form a high-strength and tough substrate through composite precipitation. Among them, PLLA provides flexibility, and n-HA (calcium-phosphorus ratio of 1.67) enhances rigidity, realizing the biphasic mechanical properties of biomimetic bone. On this basis, nano-silver particles and a drug-loaded hydrogel of Drynaria fortunei flavonoids are added. Through multiple innovations such as nano-silver antibacterial, Drynaria fortunei flavonoid anti-inflammatory and bone-promoting, and dynamic hydrogel drug release, a more comprehensive functional composite scaffold system with more complex indications is constructed, covering the multi-dimensional repair needs of supercritical bone defects, and significantly improving the technical complexity and systematicness.
[0009] To achieve the above object, the present invention adopts the following technical solutions:
[0010] In the first aspect of the present invention, a preparation method of a multifunctional biological composite scaffold for repairing supercritical bone defects is provided, including:
[0011] S1. Dissolve the organic polymer material in an organic solvent to obtain an organic polymer material solution; mix nano-hydroxyapatite, anhydrous magnesium chloride and nano-silver particles, then add them to an organic solution containing polyethylene glycol. After ultrasonic fragmentation, mix the obtained inorganic suspension with the organic polymer material solution. The resulting composite solution is miscible with absolute ethanol to produce a precipitate. The precipitate is dried to obtain a composite powder.
[0012] S2. Perform personalized bone template design on the wire obtained by extruding the composite powder to obtain a silver-magnesium composite scaffold.
[0013] S3. Drop the extracted and purified Drynaria fortunei flavone extract into the system after mixing amino-modified chitosan and aldehyde-modified xyloglucan, stir the obtained mixture and inject it into the silver-magnesium composite scaffold to obtain a multifunctional biological composite scaffold.
[0014] Preferably, in step S1, the organic polymer material is particles of poly-L-lactic acid (PLLA), poly(lactic-co-glycolic acid) (PLGA) or polycaprolactone (PCL).
[0015] Preferably, in step S1, the mass ratio of the nano-hydroxyapatite, anhydrous magnesium chloride and nano-silver particles is 4-9:1:0.03-0.17.
[0016] Preferably, in step S1, the mass ratio of the organic polymer material solution to the inorganic suspension in the composite solution is 7:3 or 6:4.
[0017] Preferably, in step S1, the organic solvent is dichloromethane, chloroform or hexafluoroisopropanol.
[0018] Preferably, in step S1, the volume ratio of the composite solution to absolute ethanol is 1:3-4.
[0019] Preferably, in step S1, the drying conditions are vacuum drying at 70°C - 80°C for 36 - 48 h.
[0020] Preferably, in step S2, the process conditions for extrusion are: the extrusion temperature is 170 - 180°C, and the standard diameter of the wire is 1.7 - 1.8 mm.
[0021] Preferably, in step S2, the personalized bone template design is carried out by placing the wire into an FDM 3D printer. Among them, the printing layer thickness is 0.1 - 0.3 mm, the pore diameter design is 100 - 500 μm, the printing speed is 55 - 65 mm / s, the nozzle diameter is 100 - 400 μm, and the nozzle diameter can be adjusted according to actual printing requirements (such as precision, speed) and the hardware configuration of different printers.
[0022] Preferably, in step S2, the personalized bone template includes cancellous bone and cortical bone. When simulating cancellous bone, the scaffold porosity is controlled at 50% to 90%, and the filling rate is controlled at 10% to 50%; when simulating cortical bone, the porosity is controlled at 5% to 10%, and the filling rate is controlled at 90% to 95%.
[0023] Preferably, in step S3, the impurity-free Drynaria flavonoid extract is obtained by dissolving the powder of the contents of the commercially available bone-strengthening capsule in ethanol, and sequentially performing dispersion, ultrasound, fluid replenishment, and filtration operations. The Chinese medicine standard number of the contents of the commercially available bone-strengthening capsule is Z20030007, and each capsule is 0.25 g.
[0024] Preferably, in step S3, the concentration of the decontaminated Drynaria flavonoids extract is 20-50 mg / mL, the mass ratio of the amino-modified chitosan to the aldehyde-modified xyloglucan is 1:1; the xyloglucan is extracted from natural plants tamarind, locust bean or guar bean; and the concentration of the Drynaria flavonoids extract in the mixed solution is 0.2-0.5 mg / mL.
[0025] The second aspect of the present invention provides a multifunctional biocomposite scaffold for repairing supercritical bone defects prepared by the above method.
[0026] The third aspect of the present invention provides the use of the multifunctional biocomposite scaffold for repairing supercritical bone defects in bone defect repair materials.
[0027] The beneficial effects achieved by one or more of the above technical solutions of the present invention are as follows:
[0028] (1) Mechanical properties: The single-material scaffolds in the prior art have poor elastic modulus and insufficient compressive strength, making them difficult to match natural bone. The present invention forms a dual-phase structure that takes both rigidity and flexibility into consideration by composite precipitation of PLLA, nanohydroxyapatite and nanosilver. The scaffold has an elastic modulus of 90-140MPa and a compressive strength of 12-18MPa, covering the mechanical requirements of cancellous bone. After 25kGy γ-ray sterilization, the mechanical property retention rate of the scaffold prepared by the present invention is ≥95%, and the nanosilver particles are not oxidatively inactivated (XPS detection of Ag + / Ago ratio remains unchanged), which means that the irradiation sterilization of the present invention has no effect on the material properties.
[0029] (2) Degradation performance: The degradation cycle of the multifunctional biocomposite scaffold prepared by the present invention can reach 12-16 weeks, which is highly matched with the bone regeneration rate (the callus formation cycle of the rat model is 12 weeks), thus avoiding the repair failure of traditional composite materials due to too fast or too slow degradation.
[0030] (3) Osteogenic performance: In the present invention, n-HA (calcium-phosphorus ratio 1.67, simulating the inorganic phase of natural bone) provides calcium and phosphorus ions. With the responsiveness of poly(L-lactic acid) and chitosan-xyloglucan hydrogel, the released magnesium ions, calcium ions and Drynaria fortunei flavonoids synergistically promote osteogenic induction. Among them, the traditional Chinese medicine active ingredient and the bone tissue engineering scaffold material significantly enhance the bone induction effect through synergy. The addition of Drynaria fortunei flavonoids (concentration 0.2 - 0.5 mg / mL) can up-regulate the expression of osteogenesis-related genes and improve the osteogenic differentiation efficiency of bone marrow mesenchymal stem cells. At the same time, the hydroxyapatite scaffold degrades and releases calcium and phosphorus ions, which synergistically promote the proliferation and differentiation of bone marrow mesenchymal stem cells and bone tissue mineralization with magnesium ions. This component can also significantly increase the expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB), etc., promote the formation of new blood vessels, improve the bone repair microenvironment, and form a multi-target synergistic bone repair network with calcium and magnesium ions.
[0031] (3) Antibacterial verification: The silver nanoparticles (particle size 5 - 50 nm) loaded on the surface of the scaffold prepared in the present invention can be found to continuously release Ag within 28 days by using atomic absorption spectrometry through sample collection, storage and treatment. + . The present invention has a high antibacterial rate against Staphylococcus aureus. The synergistic effect of silver nanoparticles and magnesium ions significantly improves the antibacterial ability against Staphylococcus aureus and Escherichia coli.
[0032] Regulation of inflammatory microenvironment: Drynaria fortunei flavonoids and hydrogel regulate the inflammatory signaling pathways (such as NF-κB, ERK, Nrf2) through multiple targets, inhibit the release of inflammatory factors, regulate the functions of immune cells, and combine with the sustained-release characteristics of the scaffold material to effectively improve the inflammatory microenvironment during bone repair and create favorable conditions for bone regeneration.
[0033] (4) Cell viability: The extract of the scaffold prepared in the present invention meets the ISO 10993 standard, and the survival rate of L929 cells is ≥ 98%. It can be concluded that the magnesium ions produced by the scaffold degradation do not produce cytotoxicity, and its concentration is controlled within a safe range.
[0034] Cytotoxicity: The metabolic pathways of the degradation products of the raw materials involved in the present invention are clear: the degradation product of PLLA is lactic acid (metabolized to CO2 and H2O through the TCA cycle), n-HA decomposes into Ca 2+ and PO4 3- (involved in bone mineralization), and silver nanoparticles and magnesium are in the form of Ag + , Mg 2+It is excreted through the kidneys. Aiming at the problem that the active ingredients of traditional Chinese medicine are prone to cause toxic reactions, the hydrogel carrier significantly improves the encapsulation efficiency of drynaria flavones by optimizing the material structure and drug loading method, and realizes the continuous and controllable release of drugs based on the slow-release mechanism. This system effectively reduces the risk of cytotoxicity caused by the burst release effect in the traditional drug delivery mode, and at the same time maintains a stable local concentration by prolonging the drug action cycle, avoiding drastic fluctuations in blood drug concentration, thus ensuring the stability of bone repair efficacy while reducing toxic and side effects. This carrier strategy provides a new idea for the safe delivery of traditional Chinese medicine components.
[0035] (5) The traditional SLS / SLA technology takes 5 - 7 days, is expensive, and the printer is bulky. While the present invention uses an inexpensive FDM 3D printer. Applying this printing technology, the whole process from image acquisition to stent implantation can be instantaneously printed in the hospital within ≤48 hours, and the porosity (5 - 90%) and pore diameter (100 - 500 μm) of the stent can be precisely regulated to match the specific bone defect morphology of the patient (CT reconstruction error ≤0.1 mm);
[0036] The reconstitution of the chitosan - xyloglucan premixed freeze - dried powder prepared by the present invention only takes 5 minutes (the traditional chemically cross - linked hydrogel takes 1 - 2 hours), and the clinical operation time is shortened by 60% - 80%. Through the design of premixed freeze - dried powder and dynamic chemical bonds, this scheme compresses the clinical operation steps from more than 10 steps to 2 steps (reconstitution + injection), and also shortens the whole process time from raw material preparation to injectable gel from several hours to within 30 minutes. Moreover, the freeze - dried powder form can extend the preservation period (room temperature preservation ≥6 months). BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The specification drawings forming a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention.
[0038] Figure 1 Scanning electron microscope image of the multifunctional biological composite stent prepared in Example 1 of the present invention;
[0039] Figure 2 Scanning electron microscope image of the freeze - dried hydrogel coating prepared in Example 1 of the present invention;
[0040] Figure 3 SEM images of the degradation of the multifunctional biological composite stent prepared in Example 1 of the present invention at different times;
[0041] Figure 4 CT image of the multifunctional biological composite stent prepared in Example 1 of the present invention implanted in a rabbit femur for one month;
[0042] Figure 5CT image of the common PLLA / n-HA scaffold prepared in Experimental Example 3 of the present invention measured one month after implantation in the rabbit femur;
[0043] Figure 6 Real-time quantitative PCR comparison chart of the osteogenic differentiation of stem cells of the multifunctional biocomposite scaffold prepared in Example 1 of the present invention and the common PLLA / n-HA scaffold;
[0044] Figure 7 Comparison chart of the expressions of VEGF and PDGF-BB between the multifunctional biocomposite scaffold prepared in Example 1 of the present invention and the PLLA / n-HA control group;
[0045] Figure 8 Comparison chart of the expressions of inflammatory factors and related signaling pathway molecules between the multifunctional biocomposite scaffold prepared in Example 1 of the present invention and the blank hydrogel scaffold without adding flavonoids of Drynaria rhizome;
[0046] Figure 9 Inhibitory effect of the multifunctional biocomposite scaffold prepared in Example 1 of the present invention on Staphylococcus aureus;
[0047] Figure 10 Inhibitory effect of the common PLLA / n-HA scaffold prepared in Experimental Example 6 of the present invention on Staphylococcus aureus:
[0048] Figure 11 Scanning electron microscope image of the silver-magnesium composite scaffold prepared during the process of Example 1 of the present invention:
[0049] Figure 12 Live-dead staining test chart of the multifunctional biocomposite scaffold prepared in Example 1 of the present invention. Detailed implementation manners
[0050] It should be noted that the following detailed description is exemplary and is intended to provide further illustration of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which the present invention belongs.
[0051] The present invention will be further described in detail below in conjunction with specific embodiments. It should be noted that the specific embodiments are explanations rather than limitations of the present invention.
[0052] In the following embodiments, the content powder of the commercially available Qianggu Capsule contains total flavonoids of Drynaria rhizome, with the national drug approval number Z20030007, and each capsule contains 0.25 g.
[0053] Example 1 :
[0054] I. Preparation of the silver-magnesium composite scaffold
[0055] (1) Preparation of organic phase solution: Dissolve PLLA particles in the organic solvent dichloromethane, and stir magnetically (500 rpm, 25 °C, 12 h) until completely dissolved.
[0056] (2) Mixing, crushing and dispersion of inorganic phase: Mix 120 g of nano-hydroxyapatite n-HA with 30 g of anhydrous magnesium chloride, then add 3 g of nano-silver particles (mass ratio in the inorganic phase), and after mixing, add it to the dichloromethane solution containing 1% PEG400 by mass fraction; Use a high-energy ultrasonic crusher to crush the inorganic phase, adjust the power to 300 W, the pulse mode is 5 seconds of work and 5 seconds of pause, the total duration is 30 minutes, and the temperature is controlled at 25 ± 5 °C in an ice bath; Transfer the crushed inorganic phase to an ultrasonic cleaner (power 360 W, frequency 40 kHz), and stir ultrasonically in water bath (12 h, water temperature 25 ± 5 °C) to form a uniform inorganic suspension.
[0057] (3) Obtaining composite precipitate and drying: Mix the organic phase solution and the inorganic phase suspension, and control the mass ratio of the organic phase / inorganic phase raw materials to be 7:3. Continue to stir ultrasonically in water bath (12 h, water temperature 25 ± 5 °C). Then slowly pour in 3 times the volume of anhydrous ethanol, stir evenly with a glass rod, and gradually precipitate white flocculent precipitate. Collect the precipitate, dry it in vacuum at 70 °C for 48 h, crush and sieve it (particle size ≤ 100 μm) to obtain Ag / Mg / PLLA / n-HA composite powder.
[0058] (4) FDM 3D printing of bare composite scaffold
[0059] Crush the Ag / Mg / PLLA / n-HA composite powder and put it into an extruder. Under the condition that the extruder temperature is 175 ± 5 °C, obtain the printing wire, and the standard diameter of the wire is 1.75 ± 0.05 mm. Put the wire into an FDM 3D printer and use a template designed according to cancellous bone to obtain a personalized printed matching scaffold.
[0060] II. Preparation of multifunctional biological composite scaffold (injecting xyloglucan hydrogel loaded with drynaria flavones into the silver-magnesium composite scaffold)
[0061] (1) Extraction of Drynaria fortunei flavonoids: Take the powder of the commercially available Qianggu capsules. Add 20 mL of absolute ethanol to each gram of the powder, and shake it on a TY-80S decolorizing shaker at 40 r / min for 30 - 60 min to preliminarily disperse the powder. Ultrasonically extract the dissolved and dispersed powder for 30 min at a frequency of 40 kHz and a power of 500 W (with temperature control function, water bath circulation cooling to prevent inactivation of active drugs due to overheating of the solvent). Control the water temperature at 25 ± 2 °C. If the equipment has no temperature control, it can be paused for 2 - 5 minutes every 10 minutes to dissipate heat. After ultrasonication, make up for the weight loss due to evaporation with absolute ethanol (it is necessary to reweigh and add absolute ethanol until the total weight = initial weight). Calibrate the total weight of the volumetric flask using an analytical balance to ensure the accuracy of the solution volume. Then seal and let it stand at room temperature of 25 °C for 10 - 20 minutes. Then place the extract containing absolute ethanol in a high-speed pre-cooled centrifuge at 4 °C and centrifuge at 12000 rpm for 15 min to remove insoluble particles and lipid impurities. Finally, take the supernatant after centrifugation, suck it with a syringe and filter it through a 0.22 μm organic nylon filter membrane (pre-wet with ethanol to reduce filtration loss) to obtain the purified Drynaria fortunei flavonoid extract (50 mg / mL), and store it sealed and protected from light in a 4 °C refrigerator.
[0062] (2) Preparation of xyloglucan hydrogel loaded with Drynaria fortunei flavonoids: Chemically modify chitosan through Schiff base reaction to make its ends rich in amino active groups. At the same time, extract from natural plants (such as tamarind, locust bean, guar bean), retain the biological activity of its natural galactoside units, and oxidize it to oxidized xyloglucan through periodate oxidation. This chemical modification endows xyloglucan with abundant aldehyde groups, enabling it to form dynamic covalent bonds with amino-modified chitosan through reversible Schiff base reaction.
[0063] Then mix the amino-modified chitosan and oxidized xyloglucan with a mass ratio of 1:1 to make a freeze-dried powder. When in use, dissolve it in PBS (mass fraction accounts for 98%) at a mass fraction concentration of 2% of the freeze-dried powder, and form a dynamic cross-linking network through reversible Schiff base reaction to achieve sol-gel transition, as Figure 2 shown. The SEM image shows the visible pore structure after freeze-drying the hydrogel coating.
[0064] Finally, slowly drip the Drynaria fortunei flavonoid extract prepared in step (1) into the hydrogel mixture system to make its concentration in the mixture system 0.3 mg / mL, and gently stir it in a magnetic stirrer at 100 - 300 r / min for 30 - 45 min to ensure uniform dispersion of each component.
[0065] (3) First, sterilize the silver-magnesium composite scaffold prepared in Step 1 by gamma rays to ensure the biological safety of the scaffold. Then, use a 34G X 3 mm needle (inner diameter about 0.18 mm), and slowly inject vertically with a syringe against the surface of the scaffold. For large-volume scaffolds, adopt a layered injection strategy (let it stand for 10 seconds after each layer injection) to ensure uniform filling, thereby obtaining a silver-magnesium composite scaffold (multifunctional biological composite scaffold) with uniform adhesion of drynaria flavone and xyloglucan hydrogel inside and outside.
[0066] As Figure 1 shown, by observing the prepared multifunctional biological composite scaffold through an electron microscope, it can be seen that n-HA and silver nanoparticles are evenly distributed on the surface, and there are no cracks, notches, or uneven surfaces, indicating that the appearance of the printed material shows uniformity.
[0067] Example 2 :
[0068] The difference between this example and Example 1 is that in Step (2), in the mixing of the inorganic phase, n-HA and anhydrous magnesium chloride are mixed at a mass ratio of 9:1, and other components and preparation methods are the same as those in Example 1.
[0069] Example 3 :
[0070] The difference between this example and Example 1 is that in Step (3), the mass ratio of the organic phase / inorganic phase raw materials is controlled to be 6:4, and other components and preparation methods are the same as those in Example 1.
[0071] Experimental Example 1 : This experimental example measures the mechanical properties of the multifunctional biological composite scaffolds prepared in Examples 1 to 3
[0072] (1) Through a standardized compression test, according to the national standards GB / T 1041-2008 "Determination of Compressive Properties of Plastics" and GB1040-79 "Test Method for Tensile Properties of Plastics", use a universal material testing machine to conduct a compression test. Place the scaffold specimens that have not been sterilized by 25 kGy gamma rays (directly inject the hydrogel system into the silver-magnesium composite scaffold) between the upper and lower pressure plates of the testing machine in turn, apply an axial compressive load at a constant loading rate (1 mm / min) until the specimen is damaged or reaches the preset deformation amount to measure the compressive strength, and analyze and calculate the elastic modulus in combination with the stress-strain curve.
[0073] The test results show that: in the present invention, through the composite precipitation of PLLA and nano-hydroxyapatite, a rigid / flexible biphasic structure is formed. The elastic moduli of Examples 1 to 3 are 124 MPa, 127 MPa, and 108 MPa respectively, and the compressive strengths are 14 MPa, 13 MPa, and 17 MPa respectively, covering the mechanical requirements of cancellous bone.
[0074] (2) Through standardized compression tests, in accordance with the national standards GB / T 1041-2008 "Determination of Compressive Properties of Plastics" and GB1040-79 "Test Method for Tensile Properties of Plastics", a universal material testing machine was used to conduct compression tests. The stent specimens (the multifunctional biological composite stent prepared in Example 1) sterilized by 25 kGy γ-ray were placed between the upper and lower pressure plates of the testing machine, and an axial compressive load was applied at a constant loading rate (1 mm / min) until the specimen was damaged or reached the preset deformation amount to measure the compressive strength, and the elastic modulus was calculated by analyzing the stress-strain curve;
[0075] By comparing and analyzing with the stent not sterilized by 25 kGy γ-ray, the elastic modulus of the sterilized stent prepared in Example 1 of the present invention is 122 MPa, and the compressive strength is 14 MPa. The retention rate of the mechanical properties of this stent is ≥95%.
[0076] Experimental Example 2 : In this experimental example, the degradation period of the multifunctional biological composite stent prepared in Example 1 was determined.
[0077] Experimental process: According to the standards of GB / T 16886.13-2017 and ISO 10993-13:2010, the mass loss rate was quantitatively determined through an in vitro simulated body fluid (SBF) immersion experiment, the change in polymer molecular weight was analyzed by gel permeation chromatography (GPC), and the morphological evolution was observed by scanning electron microscopy (SEM) to obtain the stent degradation period.
[0078] The degradation period of the stent prepared by the present invention is about 12 - 16 weeks. As Figure 3 shown in the figure of the 12th week of degradation, it can be seen that the original shape of the stent has completely disappeared and it has broken into granular form. The granules completely disappeared after degradation in about 16 weeks. The degradation situation of the stent prepared by the present invention is highly matched with the bone regeneration rate (the bone callus formation period in the rat model is 12 weeks), avoiding the problem of repair failure caused by too fast or too slow degradation of traditional composite materials.
[0079] Experimental Example 3 : In this experimental example, the osteogenic effect of the multifunctional biological composite stent prepared in Example 1 was determined.
[0080] The multifunctional biological composite stent prepared in Example 1 of the present invention and the ordinary PLLA / n-HA stent were respectively implanted into the rabbit femur for 4 weeks. The area ratio of the newly formed bone and the stent in the two-dimensional stent was obtained through CT. Among them, the stent appears gray and the newly formed bone appears white (as Figure 4 is the stent of the present invention, Figure 5 is the PLLA / n-HA stent). The software MATLAB was used to perform binary processing on the image to distinguish the osteogenic area and the stent area, and calculate the area ratio of the osteogenic area to the stent area.
[0081] The results showed that 4 weeks after implantation, the area ratio of the scaffold of the present invention to the newly formed bone area was about 7:3; while for the control group's PLLA / n-HA scaffold, the area ratio of the scaffold to the newly formed bone area was about 9:1. It can be seen that the multifunctional biological composite scaffold prepared in Example 1 of the present invention has a higher osteogenic efficiency, and the matching of scaffold degradation and new bone formation is higher. For the ordinary PLLA / n-HA scaffold in the control group, the amount of newly formed bone is less, the osteogenic efficiency is low, and the scaffold degradation is slow. This shows that the scaffold prepared by the present invention can induce the formation of new bone tissue, well promote the regeneration of critical bone defects in rabbits, and has great potential for clinical application.
[0082] Effect verification: ① Using real-time quantitative PCR (qRT-PCR) technology, designing experiments according to the MIQE guidelines, extracting total cellular RNA and reverse transcribing it into cDNA, amplifying OCN, OPN, and BMP-2 genes with specific primers, and calculating the relative expression levels;
[0083] As Figure 6 shown, it was found that compared with the control group (PLLA / n-HA scaffold), the expression levels of the multifunctional biological composite scaffold prepared in Example 1 of the present invention were all up-regulated, thereby improving the osteogenic differentiation efficiency of bone marrow mesenchymal stem cells.
[0084] ② Using enzyme-linked immunosorbent assay (ELISA), designing experiments according to the international standard ISO 15189:2022 "Requirements for the Quality and Competence of Medical Laboratories". Coating microtiter plates with specific anti-PDGF-BB antibodies, adding cell culture supernatant or tissue lysate samples, developing color with a secondary antibody labeled with horseradish peroxidase (HRP), measuring the absorbance value (OD450 nm) with an enzyme-labeled instrument, and calculating the PDGF-BB concentration based on the standard curve. Technical replicates (n≥3) and biological replicates (n≥5) were set in the experiments to verify the detection accuracy.
[0085] Using real-time quantitative PCR (qRT-PCR) technology, designing experiments according to the MIQE guidelines, extracting total cellular RNA and reverse transcribing it into cDNA, amplifying the VEGF gene with specific primers, and calculating the relative expression levels.
[0086] The data obtained from the above two Figure 7 showed that the control group was the PLLA / n-HA scaffold, and experimental groups 1-6 were multiple repeated experiments with the multifunctional biological composite scaffold prepared in Example 1; the results showed that the multifunctional biological composite scaffold prepared in Example 1 of the present invention could significantly increase the expressions of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB), etc.
[0087] Experimental Example 4: This experimental example measures the anti-inflammatory effect of the multifunctional biological composite scaffold prepared in Example 1.
[0088] Experimental procedure: For inflammatory factors TNF-a and COX-2, and the activated protein p65 downstream of the NF-κB pathway, and the activated form p-ERK (phosphorylated ERK protein) of the protein downstream of the ERK pathway, Western blot technology is used to extract the total protein of cells or tissues and quantify it (BCA / Bradford method).
[0089] Separate proteins by SDS-PAGE electrophoresis, transfer the membrane to a PVDF / NC membrane, incubate with a specific primary antibody (such as a mouse anti-human COX-2 monoclonal antibody); then bind with a secondary antibody (HRP-labeled) and develop color with ECL. For the activated molecule downstream of the Nrf2 pathway, which is the nuclear Nrf2 protein (n-Nrf2), nuclear protein separation technology is additionally required.
[0090] First, treat cells with oxidative stress inducers (such as tBHQ, sulforaphane), extract nuclear proteins using a nuclear protein extraction kit, and then perform Western Blot technology to develop and analyze the expression level of nuclear Nrf2 protein.
[0091] The results of the above verification are plotted into a statistical chart, that is Figure 8 , the control group is the scaffold prepared from the hydrogel mixture system without drug loading in Example 1 of the present invention, and the experimental group is the multifunctional biological composite scaffold (drynaria flavonoid hydrogel group) prepared in Example 1 of the present invention. The results show that drynaria flavonoid and hydrogel regulate the inflammatory signaling pathway (such as NF-κB, ERK, Nrf2) through multiple targets, inhibit the release of inflammatory factors, and regulate the function of immune cells.
[0092] Experimental Example 5 : This experimental example measures the antibacterial effect of the multifunctional biological composite scaffold prepared in Example 1.
[0093] Experimental procedure: Place the scaffold (experimental group) prepared in Example 1 of the present invention and a common PLLA / n-HA scaffold (control group) respectively in a Staphylococcus aureus bacterial suspension (concentration 1×10 6 CFU / mL), and co-culture at 37°C for 24 hours. Subsequently, take 100 μL of the bacterial solution after co-culture of each group and evenly coat it on the surface of an agar plate, and continue to incubate for 24 hours and then perform colony counting analysis.
[0094] The experimental results showed that: on the control group plate, dense colonies of Staphylococcus aureus could be seen (about 478 colonies), while the number of colonies on the experimental group plate was significantly less (about 298 colonies). By using ImageJ software to perform semi-quantitative analysis on the colony distribution density, the proportion of the antibacterial area in the experimental group reached 98.2%, which was significantly higher than 62.5% of the control group. This result intuitively confirmed that the silver nanoparticles in the scaffold prepared in Example 1 of the present invention had a highly efficient inhibitory effect on Staphylococcus aureus.
[0095] The experimental results are as Figures 9 - 10 shown, Figure 9 which are the culture results of Staphylococcus aureus of the present invention, Figure 10 and the colony culture results of the ordinary PLLA / n-HA scaffold. It can be seen that the number of Staphylococcus aureus colonies cultured on the scaffold of the present invention is about 100, and the antibacterial area is as high as 98.2%. Compared with the control group, it shows highly efficient antibacterial properties.
[0096] Experimental Example 6 : In this experimental example, the biocompatibility and cell viability of the multifunctional bio-composite scaffold prepared in Example 1 were detected.
[0097] (1) Scaffold imaging experiment: (1) Scaffold imaging experiment: Using an FDM printer of model Factor 4, adjusting relevant parameters on the slicing software to make the pore diameter of the scaffold 300 microns, the porosity 55%, using a wire of 2.85 mm, and adjusting the appropriate nozzle diameter according to the different printing layers of the model, selecting a certain filling path and direction for filling. The printing speed needs to match the extrusion flow rate, and the filling speed is set to 50 mm / s. Adjust the nozzle temperature to 175 °C to ensure the regularity of the scaffold structure. After printing, observe the morphological distribution of the surface and internal pores of the scaffold through the SEM imaging system. As Figure 11 shown.
[0098] (2) Live / dead staining experiment: Co-culture the multifunctional bio-composite scaffold prepared in Example 1 with bone marrow mesenchymal stem cells for 12 hours, and then use calcein (Calcein-AM, green fluorescence) to label the surviving cells (metabolically active cells can convert Calcein-AM into green fluorescent substances), and use propidium iodide (PI, red fluorescence) to label the dead cells. Gently rinse with PBS to remove the unbound dyes, avoiding mechanical damage that may cause false positives. Observe the distribution of cell survival (green) and death (red) through a fluorescence microscope, and image the surface morphology of the scaffold and the cell adhesion state through a scanning electron microscope (SEM), and perform composite analysis with the above fluorescence images.
[0099] As Figure 12As shown, a large number of uniformly distributed green fluorescent signals (live cells) were visible on the surface of the scaffold, indicating that the BMSCs were in good survival condition. No red fluorescent signals (dead cells) were observed. The possible reasons are speculated as follows: the scaffold itself has extremely low cytotoxicity and does not trigger cell death; a very small number of dead cells detached from the surface of the scaffold during the PBS rinsing process. SEM imaging: The cells adhered tightly along the three-dimensional pore structure of the scaffold, with good morphological extension, and no shrinkage or rupture. n-HA and silver nanoparticles were uniformly distributed on the surface of the scaffold, without sharp protrusions or structural defects (to avoid physical damage to cells).
[0100] By calculating the survival rate (Calculation of survival rate = number of live cells / (number of live cells + number of dead cells)), it was obtained that the cell survival rate was approximately 100%, indicating that the invented scaffold has good biocompatibility and cell affinity, can provide a suitable microenvironment for cells, support their adhesion, proliferation and subsequent osteogenic differentiation, verified the biological safety basis of its use as a bone repair material, and in the composite imaging of the scaffold and cells, it was visible that the cells could grow along the scaffold without biological toxicity.
[0101] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention can have various changes and modifications. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.
Claims
1. A preparation method of a multifunctional biological composite scaffold for repairing supercritical bone defects, characterized in that, Including: S1. Dissolve the organic polymer material in an organic solvent to obtain an organic polymer material solution; mix nano-hydroxyapatite, anhydrous magnesium chloride and nano-silver particles, then add them to an organic solution containing polyethylene glycol, and mix the obtained inorganic suspension, which is obtained by ultrasonic fragmentation, with the organic polymer material solution. The obtained composite solution is miscible with absolute ethanol to produce a precipitate, and the precipitate is dried to obtain composite powder; S2. Perform personalized bone template design on the wire obtained by extruding the composite powder to obtain a silver-magnesium composite scaffold; S3. Drop the extracted and impurity-removed drynaria flavone extract into the system after mixing amino-modified chitosan and aldehyde-modified xyloglucan, stir the obtained mixture and inject it into the silver-magnesium composite scaffold to obtain a multifunctional biological composite scaffold.
2. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, characterized in that, In step S1, the organic polymer material is particles of poly-L-lactic acid PLLA, poly(lactic-co-glycolic acid) PLGA or polycaprolactone PCL.
3. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, wherein, In step S1, the mass ratio of the nano-hydroxyapatite, anhydrous magnesium chloride and nano-silver particles is 4-9:1:0.03-0.17; Preferably, the mass ratio of the organic polymer material solution to the inorganic suspension in the composite solution is 7:3 or 6:
4.
4. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, characterized in that, The organic solvent is dichloromethane, chloroform or hexafluoroisopropanol.
5. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, characterized in that, The volume ratio of the composite solution to absolute ethanol is 1:3-4; Preferably, the drying conditions are vacuum drying at 70°C - 80°C for 36 - 48 h.
6. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, characterized in that, In step S2, the process conditions for extrusion are: the extrusion temperature is 170 - 180°C, and the standard diameter of the wire is 1.7 - 1.8 mm.
7. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, characterized in that, In step S2, the personalized bone template design is operated by placing the wire into an FDM 3D printer, wherein the printing layer thickness is 0.1 - 0.3 mm, the pore diameter design is 100 - 500 μm, the printing speed is 55 - 65 mm / s, the nozzle diameter of TNF-α spray is 100 - 400 μm, and the nozzle diameter is adjusted according to the actual printing requirements and the hardware configuration of different printers; Preferably, the impurity-removed drynaria flavone extract is obtained by dissolving the content powder of commercially available Qianggu capsules in ethanol and performing dispersion, ultrasonic treatment, liquid supplement and filtration operations in sequence. The national drug approval number of the content of the commercially available Qianggu capsules is Z20030007, and each capsule is 0.25 g.
8. The preparation method of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 1, wherein, In step S3, the concentration of the impurity-removed drynaria flavone extract is 20 - 50 mg / mL, the mass ratio of the amino-modified chitosan to the aldehyde-modified xyloglucan is 1:1; the xyloglucan is extracted from natural plants such as tamarind, locust bean or guar bean; the concentration of the drynaria flavone extract in the mixture is 0.2 - 0.5 mg / mL.
9. A multifunctional biological composite scaffold for repairing supercritical bone defects prepared by the method according to any one of claims 1 - 8.
10. Use of the multifunctional biological composite scaffold for repairing supercritical bone defects according to claim 9 in bone defect repair materials.
Citation Information
Patent Citations
Modified zinc oxide-based bone implantation scaffold material as well as forming method and preparation method thereof
CN119499449A
Cited By
Three-dimensional porous bioactive scaffold, vascularized bone organ as well as preparation method and application of three-dimensional porous bioactive scaffold and vascularized bone organ
CN122075798A
